Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.
Saved in:
| Title: | Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide. |
|---|---|
| Authors: | Systchenko T; Poitou-Charentes General Cancer Registry, Université de Poitiers, Poitiers, France.; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France., Nsiala L; Poitou-Charentes General Cancer Registry, Université de Poitiers, Poitiers, France.; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France., Bobin A; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France., Gardeney H; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France., Motard C; Hematology Department, Hospital Center of Niort, Niort, France., Olivier G; Hematology Department, Hospital Center of Niort, Niort, France., Borde F; Oncology Department, Hospital Center of Saintes, Saintes, France., Corby A; Hematology Department, Hospital Center of La Rochelle, La Rochelle, France., Roul C; Hematology Department, Hospital Center of La Rochelle, La Rochelle, France., Fleck E; Hematology Department, Hospital Center of La Rochelle, La Rochelle, France., Denis G; Internal Medicine Department, Hospital Center of Rochefort, Rochefort, France., Dieval C; Internal Medicine Department, Hospital Center of Rochefort, Rochefort, France., Mottaz P; Internal Medicine Department, Hospital Center of Royan, Royan, France., Boscagli A; Internal Medicine Department, Hospital Center of Royan, Royan, France., Defossez G; Poitou-Charentes General Cancer Registry, Université de Poitiers, Poitiers, France.; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France., Leleu X; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France. |
| Source: | Blood advances [Blood Adv] 2025 Dec 09; Vol. 9 (23), pp. 6001-6008. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
